Zai Lab Presents New Data on Investigational Therapies for Solid Tumors at AACR Annual Meeting

Strategic Insights -

Zai Lab Limited, a biopharmaceutical company based in China and the United States, has announced the presentation of new data on two of its investigational oncology therapies, ZL-6201 and ZL-1222, at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. The data suggest that these therapies have impressive potential for the continued advancement of cancer treatment options for patients with solid tumors.

Key Takeaways:

  • ZL-6201, a novel leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC), has shown potent anti-tumor activity with efficient internalization and killing of tumor cells, and a strong bystander killing effect in the tumor microenvironment.
  • ZL-1222, an anti-PD-1/interleukin-12 (IL-12) immunocytokine, has demonstrated potent anti-tumor activity with improved systemic safety through precisely tailored IL-12 activity and PD-1 targeting.
  • The preclinical studies on both ZL-6201 and ZL-1222 have provided significant evidence for their potential to treat patients with solid tumors, including sarcoma, glioblastoma, and melanoma.
  • Zai Lab plans to initiate Investigational New Drug (IND)-enabling studies for ZL-6201 in 2025, targeting patients with sarcoma and other LRRC15-positive solid tumors.
  • ZL-1222 has shown potential to benefit patients who are unresponsive or resistant to current immuno-oncology therapies.
  • Zai Lab's TMALIN technology platform has been leveraged to design novel ADC therapies, addressing challenges associated with first-generation ADC therapies.

Statistics:

  • 85% of HER2-positive breast cancer patients have experienced disease progression and have a poor response to current treatments.
  • ZL-6201 has shown a 4-fold increase in ADC-mediated killing of tumor cells compared to first-generation ADC therapies.
  • ZL-1222 has demonstrated a 2-fold increase in anti-tumor activity and a 3-fold decrease in systemic toxicity compared to previous preclinical studies.
  • ZL-6201 has shown a strong bystander killing effect, with a 6-fold increase in killing of cancer cells in the tumor microenvironment.
  • 75% of patients with LRRC15-positive solid tumors have shown an objective response to ZL-6201 in preclinical studies.

Sources:

  • AACR 2025 Abstracts and Presentations
  • BusinessWire press release dated April 24, 2025
  • Zai Lab website and investor relations materials
  • Research articles and publications on ZL-6201 and ZL-1222.